Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been newly diagnosed with one of the following types of T-cell lymphoma (and have not yet received treatment): angioimmunoblastic T-cell lymphoma, follicular helper T-cell lymphoma, or peripheral T-cell lymphoma with follicular helper T-cell type
• People who were between 20 and 85 years old at the time of diagnosis
• People who are reasonably active and able to care for themselves (a doctor would assess this using a standard scale called the ECOG scale, scoring 0, 1, or 2)
• People whose heart is pumping well enough to tolerate chemotherapy, as confirmed by a heart scan
• People whose kidneys are functioning at an adequate level, as confirmed by blood tests
• People whose liver is functioning at an adequate level, as confirmed by blood tests
• People whose blood cell counts (white blood cells and platelets) are at adequate levels, as confirmed by blood tests (lower thresholds may apply if the lymphoma has affected the bone marrow)
• People who are willing and able to give written consent to take part in the study
• People who are able to attend scheduled study visits and follow the study requirements
• Women who could become pregnant must have a negative pregnancy test before joining
• Women who could become pregnant, and men, must agree to use effective contraception during the study and for 3 months after it ends
• People with a life expectancy of at least 3 months
• People who are carriers of hepatitis B, or who have inactive hepatitis C with normal liver enzyme levels, may be eligible provided they are taking appropriate preventive antiviral medication

Who may not be able to join:

• People diagnosed with other subtypes of non-Hodgkin's lymphoma
• People who have received chemotherapy for Hodgkin's lymphoma or other non-Hodgkin's lymphoma within the past 5 years
• People who have had an active cancer diagnosed within the past 3 years (certain exceptions may apply, such as fully removed non-melanoma skin cancer, papillary thyroid cancer, early-stage cervical or breast cancer, or localised prostate cancer — confirm with trial site)
• People with uncontrolled hepatitis B (some exceptions may apply for people with no symptoms who are receiving antiviral treatment — confirm with trial site)
• People with a history of chronic hepatitis C (some exceptions may apply — confirm with trial site)
• People with a history of HIV infection
• People with moderate to severe heart failure
• People who have had a heart attack, unstable chest pain, or a serious irregular heartbeat within the past 6 months
• People with a history of major neurological or psychiatric illness, including dementia or epilepsy
• People with severe chronic lung disease that causes low oxygen levels
• People who have had a stroke or a mini-stroke (TIA) within the past 3 months
• People with wounds, ulcers, or bone fractures that have not healed
• People with active infections that are not under control
• People who are currently taking another experimental drug as part of a different study
• People with a known allergy or sensitivity to any of the drugs used in this trial
• People who have had major surgery or a serious injury within the past 21 days, or a surgical biopsy within the past 7 days
• Men who have not had a vasectomy and whose partner plans to become pregnant, or who are unable to use an accepted method of contraception during the study
• Women who are pregnant or breastfeeding, or women and men who are unwilling to use appropriate contraception during the study
• People who have previously received immunotherapy or chemotherapy for T-cell lymphoma (a short course of steroid treatment lasting fewer than 8 days may be an exception — confirm with trial site)
• People who have previously received radiation therapy, except where it was limited to a single lymph node
• People whose lymphoma has spread to the central nervous system (brain or spinal cord)
• People for whom any of the chemotherapy drugs used in this trial are medically unsuitable
• People who have previously received more than 200 mg/m² of a chemotherapy drug called doxorubicin

Important: Always verify eligibility with the trial site directly before applying.